非甾体抗炎药与阿片类药物治疗膝髋骨关节炎的有效性和安全性:网络荟萃分析
结果显示依托考昔60 mg/日和双氯芬酸150 mg/日似乎是最有效的口服NSAIDs,但不良事件风险略增;局部双氯芬酸70-81 mg/日有效且更安全,可考虑作为膝骨关节炎一线药物治疗;阿片类的临床获益不抵其危害。
要点
- 依托考昔60 mg/日和双氯芬酸150 mg/日似乎是最有效的口服NSAIDs。
- 局部双氯芬酸70-81 mg/日有效且更安全,可考虑作为膝骨关节炎一线药物治疗。
- 阿片类无论剂型或剂量,其临床获益不抵可能造成的危害。
核心结论
- 依托考昔60 mg/日和双氯芬酸150 mg/日似乎是骨关节炎疼痛和功能最有效的口服NSAIDs,但可能不适合合并症患者或长期使用。
- 局部双氯芬酸70-81 mg/日似乎有效且因全身暴露减少和剂量较低而更安全,应被视为膝骨关节炎一线药物治疗。
- 阿片类治疗的临床获益无论剂型或剂量均不抵其可能造成的危害。
研究设计与样本
- 系统综述与随机试验的网络荟萃分析,检索CENTRAL、Medline、Embase、监管机构网站和ClinicalTrials.gov至2021年6月28日。
- 纳入每组至少100例患者、评估NSAIDs、阿片类或对乙酰氨基酚治疗骨关节炎的英文随机试验。
主要发现
- 五种口服制剂(双氯芬酸150 mg/日、依托考昔60和90 mg/日、罗非昔布25和50 mg/日)在疼痛改善超过最小临床重要差异方面概率≥99%。
- 局部双氯芬酸(70-81和140-160 mg/日)概率≥92.3%,所有阿片类概率≤53%。
- 口服NSAIDs、局部NSAIDs和阿片类中因不良事件退出风险增加的比例分别为18.5%、0%和83.3%;任何不良事件风险增加的比例分别为29.8%、0%和89.5%。
- 羟吗啡酮80 mg/日因不良事件退出风险(51%)和任何不良事件风险(88%)最高。
临床怎么用
- 依托考昔60 mg/日和双氯芬酸150 mg/日可用于骨关节炎疼痛和功能改善,但需考虑合并症和长期使用的不良事件风险。
- 局部双氯芬酸70-81 mg/日可考虑作为膝骨关节炎一线药物治疗。
- 阿片类药物治疗骨关节炎的临床获益不抵其危害,应谨慎使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effectiveness and safety of different preparations and doses of non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and paracetamol for knee and hip osteoarthritis pain and physical function to enable effective and safe use of these drugs at their lowest possible dose. DESIGN: Systematic review and network meta-analysis of randomised trials. DATA SOURCES: Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, regulatory agency websites, and ClinicalTrials.gov from inception to 28 June 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised trials published in English with ≥100 patients per group that evaluated NSAIDs, opioids, or paracetamol (acetaminophen) to treat osteoarthritis. OUTCOMES AND MEASURES: The prespecified primary outcome was pain. Physical function and safety outcomes were also assessed. REVIEW METHODS: Two reviewers independently extracted outcomes data and evaluated the risk of bias of included trials. Bayesian random effects models were used for network meta-analysis of all analyses. Effect estimates are comparisons between active treatments and oral placebo. RESULTS: 192 trials comprising 102 829 participants examined 90 different active preparations or doses (68 for NSAIDs, 19 for opioids, and three for paracetamol). Five oral preparations (diclofenac 150 mg/day, etoricoxib 60 and 90 mg/day, and rofecoxib 25 and 50 mg/day) had ≥99% probability of more pronounced treatment effects than the minimal clinically relevant reduction in pain. Topical diclofenac (70-81 and 140-160 mg/day) had ≥92.3% probability, and all opioids had ≤53% probability of more pronounced treatment effects than the minimal clinically relevant reduction in pain. 18.5%, 0%, and 83.3% of the oral NSAIDs, topical NSAIDs, and opioids, respectively, had an increased risk of dropouts due to adverse events. 29.8%, 0%, and 89.5% of oral NSAIDs, topical NSAIDs, and opioids, respectively, had an increased risk of any adverse event. Oxymorphone 80 mg/day had the highest risk of dropouts due to adverse events (51%) and any adverse event (88%). CONCLUSIONS: Etoricoxib 60 mg/day and diclofenac 150 mg/day seem to be the most effective oral NSAIDs for pain and function in patients with osteoarthritis. However, these treatments are probably not appropriate for patients with comorbidities or for long term use because of the slight increase in the risk of adverse events. Additionally, an increased risk of dropping out due to adverse events was found for diclofenac 150 mg/day. Topical diclofenac 70-81 mg/day seems to be effective and generally safer because of reduced systemic exposure and lower dose, and should be considered as first line pharmacological treatment for knee osteoarthritis. The clinical benefit of opioid treatment, regardless of preparation or dose, does not outweigh the harm it might cause in patients with osteoarthritis. SYSTEMATIC REVIEW REGISTRATION: PROSPERO number CRD42020213656.
引用
- da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021. PMID: 34642179. doi:10.1136/bmj.n2321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。